Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baraclude for HBV Recurrence Prevention After Liver Transplant
NCT00395018Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2007
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of entecavir in chronic hepatitis B virus infection (CHB), sponsored by Bristol Myers Squibb. Primary endpoints: Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) >= 50 IU/mL at 72 weeks and Number of Participants With HBV DNA by PCR >= 50 IU/mL Through Week 72. Started Apr 2007; status: completed.
02
Drugs
entecavir
03
Conditions
chronic hepatitis B virus infection (CHB)
Beyond the preview
Go deeper on NCT00395018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395018.